annual report 2008 - Pevion Biotech AG

More documents

Recommendations

Info

2008 ANNUAL REPORT 2 C O N T E N T S LETTER FROM THE CEO .................................................................................... 3 HIGHLIGHTS 2008 ............................................................................................... 4 COMPANY PROFILE ........................................................................................... 5 MANAGEMENT................................................................................................... 5 BOARD OF DIRECTORS ..................................................................................... 6 SCIENTIFIC ADVISORY BOARD ......................................................................... 7 VIROSOME-BASED TECHNOLOGY .................................................................. 8 LEAD PROJECTS 2008 ........................................................................................ 9 INTELLECTUAL PROPERTY .............................................................................. 13 Pevion_Biotech_annual_report_2008_final.docx
2008 ANNUAL REPORT 3 L E T T E R F R O M T H E C E O D E A R S H A R E H O L D E R , Pevion_Biotech_annual_report_2008_final.docx 2008 A N N U A L R E P O R T I am delighted to present our 2008 annual report. 2008 was a milestone year in the history of Pevion Biotech. In July the company moved into its new premises in Ittigen near Bern/Switzerland. The new premises have a total of 1600 m 2 , including 800 m 2 of laboratory space equipped with state-of-the-art laboratories. The new laboratories have been designed to meet Pevion Biotech's requirements. They provide a basis on which the company can develop its products at highest standards also in the future. Pevion Biotech now has enough laboratory and office space to allow the company to grow and hire employees required for the later stage development of the products. The smooth relocation was only possible because of the tremendous motivation and enthusiasm of all Pevion employees and specifically the ones who managed the whole reconstruction of the new premises. The professionalism of this relocation is also observable by the fact that the whole team was completely operational within one week after moving to the new premises. To a considerable extent, the relocation of the company has also been supported by the Bern Economic Development Agency. I am convinced that the relocation represents a cornerstone for Pevion Biotech to continue its sustained growth. As an effect of the relocation, the company had to renew its license for manufacturing of investigational medicinal products. The Swiss Agency for Therapeutic Products (Swissmedic) inspected the company in early October 2008. The company passed the inspection without any major issues and even received an extended license which additionally includes the market release of the investigational medicinal products. Regarding Pevion Biotech's vaccine candidates, in 2008 the company finalized the acquisition and licensing of its most advanced product, the vaccine against malaria infections. Pevion Biotech has already earned substantial milestone payments based on this license. This puts Pevion Biotech in a very good financial position and offers a promising outlook for 2009. Pevion Biotech has now grown to 22 employees, whereas 17 of them work in R&D. In 2009, the company will further extend its expertise, especially in the area of clinical development and regulatory affairs. This will allow us a thorough development of the vaccine candidates until clinical Phase II. I want to thank our employees for their dedication and hard work, and I am convinced that with the support of this enthusiastic and experienced team, Pevion Biotech will advance its vaccine candidates to the point where they can be partnered. I am looking forward to all new challenges, to increasing the value of the company significantly and to promoting the promising virosome technology. Sincerely, Dr. Thomas Stauffer CEO Pevion Biotech AG
Page 1: annual report 2008 Pevion Biotech L
Page 5 and 6: 2008 ANNUAL REPORT 5 C O M P A N Y
Page 7 and 8: 2008 ANNUAL REPORT 7 S C I E N T I
Page 9 and 10: 2008 ANNUAL REPORT 9 L E A D P R O
Page 11 and 12: 2008 ANNUAL REPORT 11 Need for a Ca
Page 13 and 14: 2008 ANNUAL REPORT 13 I N T E L L E

annual report 2008 - Pevion Biotech AG

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?